

REMARKS


Claims 1-6, 8 and 15-25 have been canceled. Claims 1-6 and 8 have been canceled as certain aspects of these claims are the subject matter allowed in U.S. patent application number 10/158,649. Applicants hereby cancel claims 1-6 and 8 without waiver or prejudice to filing a divisional application directed to the subject matter of these claims outside of that allowed in U.S. patent application number 10/158,649. Claims 15-17 have been canceled without waiver or prejudice to filing a divisional application directed to these claims. Claims 18-25 have been canceled as these claims are the subject matter of U.S. patent application number 09/380,186, now U.S. Patent 6,448,263. Claim 7 was amended in order to put it into independent form whereas this claim previously depended from claim 1. The definition of the compound of formula I from claim 1 was introduced into claim 7 by this amendment. Applicants submit no new matter was introduced by this amendment.

On the basis of the above amendments and remarks, applicants believe this application, as amended, is in condition for allowance and its early allowance is respectfully requested.

Respectfully submitted,

Date: 22 JULY 2003

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-6645

  
John A. Wichrowski  
Attorney for Applicant(s)  
Reg. No. 48,032